サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1122233

感染症体外診断の市場規模、シェア、動向分析レポート：製品別（機器、試薬）、アプリケーション別（HPV、HIV）、技術別、検査部位別、セグメント別予測、2022年～2030年

Infectious Disease In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Application (HPV, HIV), By Technology, By Test Location, And Segment Forecasts, 2022 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
感染症体外診断の市場規模、シェア、動向分析レポート：製品別（機器、試薬）、アプリケーション別（HPV、HIV）、技術別、検査部位別、セグメント別予測、2022年～2030年
出版日: 2022年08月29日
発行: Grand View Research
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

感染症体外診断市場の成長と動向

Grand View Research, Inc.の最新レポートによると、感染症体外診断の世界市場規模は、2022年から2030年にかけてCAGR-7.4%を記録し、2030年までに566億米ドルに達すると予測されています。結核やCOVID-19などの感染症の有病率の上昇と技術の進歩が、今後数年間の製品需要を促進すると予測されています。多剤耐性感染症の増加により、感染症の早期診断が強化されています。例えば、MDR感染症はICU患者に非常に多く、2021年のMicrobial Drug Resistance Journalによると、重症のSARS-CoV-2患者におけるMDR感染症の有病率は14%から50%の間であったとされています。

感染症診断前の診断と抗生物質による治療の遅れは、薬剤耐性菌の蔓延をさらにエスカレートさせ、業界成長のための有利な機会を作り出しています。業界では、消費者の需要に応えるため、相当数の製品の上市が行われています。例えば、2022年5月、BDは米国で感染症用自動診断プラットフォームを発表しました。このシステムは1700検体の搭載を可能にし、検体の選別の必要性も排除されるため、エラーを減らすことができます。様々な競合企業が提供する製品は、競争企業間の敵対関係を高めるために戦略的な価格設定を行っています。

しかし、POC検査とラボ検査では感度や考え方が異なるため、消費者がどちらかを選択しなければならない場合、購買行動の複雑さが顕著になります。業界は寡占状態にあり、Hoffmann-La Roche Ltd.、Alere、bioMerieux、BDなどの企業がまとめてシェアの大半を占めています。世界の業界は価格に敏感で、費用対効果の高い効率的な製品の製造という点で、プレイヤー間の厳しい競争を生みだしています。新規バイオマーカーキットの発売が予想されることから、競争企業間の敵対関係は予測期間中に強まることが予想されます。競合他社は、より高い市場シェアを獲得するために、製品の発売や啓蒙活動の実施など、重要な戦略を採用しています。

感染症体外診断市場レポートハイライト

試薬製品セグメントは、検査での大量使用により、2021年に最大の売上高シェアを占めました。

分子診断薬セグメントは、同セグメントにおける製品上市数の増加や、高い精度による採用の増加により、2021年に最大のシェアを占めました。

用途別では、ウイルスの蔓延を抑えるために検査への支出が多いCOVID-19分野が2021年に業界を席巻した

中央研究所セグメントは、研究所ベースの検査の精度が高いため、PoCや家庭での検査と比較して信頼性が高く、これらの検査が他の2つのセグメントに対して競争力を持つことから、2021年に最高の収益シェアを占めた

北米は、良好な規制の枠組み、予防および早期検査への注力、この地域における新規診断薬の高い採用率により、2021年に世界の業界を支配した

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
    • 製品
    • テクノロジー
    • 応用
    • テスト場所
    • 地域範囲
  • 調査手法
  • 情報調達
    • 購入したデータベース
    • GVRの内部データベース
    • 二次情報
    • 1次調査
    • 1次調査内容
      • 北米の一次面接データ
      • 欧州での一次インタビューのデータ
      • アジア太平洋地域の一次インタビューのデータ
      • 中東・アフリカの一次面接データ
  • 情報またはデータ分析
    • データ分析モデル
  • 市場の策定と検証
  • モデルの詳細
    • コモディティフロー分析（モデル1）
      • アプローチ1：コモディティフローアプローチ
  • 二次情報一覧
  • 略語一覧
  • 目的

第2章 エグゼクティブサマリー

  • 市場の見通し
  • セグメントの洞察
  • 競合考察

第3章 感染症体外診断市場の変数、動向、範囲

  • 市場系列の見通し
    • 親会社の市場見通し
  • 浸透と成長の見通しのマッピング
  • ユーザー視点分析
    • 消費者行動分析
    • 市場インフルエンサー分析
    • 主要なエンドユーザーのリスト
  • 規制の枠組み
  • 市場力学
    • 市場促進要因分析
      • 高齢者人口の増加
      • 技術の進歩
      • PoC施設への高い需要
      • 感染症の蔓延
      • 研究開発活動のための外部資金
    • 市場抑制分析
      • IVD検査の高価格
    • 業界の課題
      • あいまいな規制の枠組みの存在
  • 感染症体外診断市場分析ツール
    • 業界分析- ポーターの5つの力
    • PESTLE分析
    • 主要な取引と戦略的提携の分析
      • 新製品の発売
      • 合併と買収
      • 拡張
      • パートナーシップ
      • マーケティングとプロモーション
    • 市場参入戦略

第4章 感染症体外診断市場-セグメント分析、製品別、2018年から2030年（100万米ドル）

  • 定義と範囲
  • 製品タイプの市場シェア分析、2021年および2030年
  • セグメントダッシュボード
  • 世界の感染症体外診断市場、製品別、2018年から2030年
  • 市場規模と予測、トレンド分析、2018年から2030年
    • 機器
    • 試薬
    • ソフトウェア

第5章 感染症体外診断市場-セグメント分析、テクノロジー別、2018年から2030年（100万米ドル）

  • 定義と範囲
  • テクノロジータイプの市場シェア分析、2021年および2030年
  • セグメントダッシュボード
  • 世界の感染症体外診断市場、技術別、2018年から2030年
  • 市場規模と予測、トレンド分析、2018年から2030年
    • イムノアッセイ
    • 分子診断学
      • ポリメラーゼ連鎖反応（PCR）
      • in situハイブリダイゼーション
      • 等温核酸増幅技術（INAAT）
      • チップとマイクロアレイ
      • シーケンシングとNGS
      • 転写媒介増幅
      • その他
    • 微生物学
    • その他

第6章 感染症体外診断市場-セグメント分析、アプリケーション別、2018年から2030年（100万米ドル）

  • 定義と範囲
  • アプリケーションタイプの市場シェア分析、2021年および2030年
  • セグメントダッシュボード
  • 世界の感染症体外診断市場、アプリケーション別、2018年から2030年
  • 市場規模と予測、トレンド分析、2018年から2030年
    • MRSA
    • 連鎖球菌
    • クロストリジウム・ディフィシル
    • バンコマイシン耐性腸球菌（VRE）
    • カルバペネム耐性腸内細菌検査（CRE）
    • 呼吸器ウイルス
    • カンジダ
    • 結核（TB）と薬剤耐性結核
    • 胃腸（GI）パネル検査
    • クラミジア
    • 淋病
    • ヒトパピローマウイルス（HPV）
    • ヒト免疫不全ウイルス（HIV）
    • C型肝炎
    • B型肝炎
    • COVID-19）
    • その他

第7章 感染症体外診断市場-セグメント分析、テスト場所別、2018年から2030年（100万米ドル）

  • 定義と範囲
  • テスト場所の種類の市場シェア分析、2021年および2030年
  • セグメントダッシュボード
  • 世界の感染症体外診断市場、検査場所別、2018年から2030年
  • 市場規模と予測、トレンド分析、2018年から2030年
    • 注意する点
    • 中央研究所
    • その他

第8章 感染症体外診断市場-セグメント分析、地域別、2018年から2030年（100万米ドル）

  • 定義と範囲
  • 地域市場シェア分析、2021年および2030年
  • 地域市場ダッシュボード
  • 地域市場のスナップショット
  • 2021年の地域市場シェアと主要企業
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東とアフリカ
  • SWOT分析
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東とアフリカ
  • 市場規模、予測、収益、トレンド分析、2021年から2030年
    • 北米
      • 米国
      • カナダ
    • 欧州
      • 英国
      • ドイツ
      • スペイン
      • フランス
      • イタリア
    • アジア太平洋地域
      • 日本
      • 中国
      • インド
      • 韓国
      • オーストラリア
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • アルゼンチン
    • MEA
      • 南アフリカ
      • サウジアラビア
      • アラブ首長国連邦

第9章 競合情勢

  • 主要な市場参加者別最近の動向と影響分析
    • Ansoff matrix
    • Heat map analysis
  • 会社の分類
    • イノベーター
    • 市場のリーダー
  • ベンダー情勢
    • 主要なディストリビューターとチャネルパートナーのリスト
    • 主要顧客
    • 主要企業の市場シェア分析、2021年
  • 公開会社
    • 企業の市況分析
    • 企業の市場シェア、地域別、2021年
    • 競合ダッシュボード分析
      • 市場の差別化要因
  • プライベートカンパニー
    • 主要新興企業一覧
  • 企業プロファイル
    • BD
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • bioMerieux SA
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Abbott
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Quidel Corporation
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • OraSure Technologies, Inc
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Hologic Inc.（Gen-Probe）
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Cepheid（Danaher）
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • QIAGEN
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • F. Hoffmann-La Roche Ltd.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Siemens Healthcare GmbH
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Bio-Rad Laboratories, Inc.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
図表

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Regulatory Framework
  • TABLE 4 Global IVD Infectious Diseases Market, By Region, 2018 - 2030 (USD Million)
  • TABLE 5 Global IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 6 Global IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 7 Global IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 8 Global IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 9 North America IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 10 North America IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 11 North America IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 12 North America IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 13 North America IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 14 U.S. IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 15 U.S. IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 16 U.S. IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 17 U.S. IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 18 Canada IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 19 Canada IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 20 Canada IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 21 Canada IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 22 Europe IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 23 Europe IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 24 Europe IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 25 Europe IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 26 Europe IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 27 U.K. IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 28 U.K. IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 29 U.K. IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 30 U.K. IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 31 Germany IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 32 Germany America IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 33 Germany America IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 34 Germany America IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 35 France IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 36 France IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 37 France IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 38 France IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 39 Spain IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 40 Spain IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 41 Spain IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 42 Spain IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 43 Italy IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 44 Italy IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 45 Italy IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 46 Italy IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 47 Asia Pacific IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 48 Asia Pacific IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 49 Asia Pacific IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 50 Asia Pacific IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 51 Asia Pacific IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 52 China IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 53 China IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 54 China IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 55 China IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 56 Japan IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 57 Japan IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 58 Japan IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 59 Japan IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 60 India IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 61 India IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 62 India IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 63 India IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 64 South Korea IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 65 South Korea IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 66 South Korea IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 67 South Korea IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 68 Singapore IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 69 Singapore IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 70 Singapore IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 71 Singapore IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 72 Australia IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 73 Australia IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 74 Australia IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 75 Australia IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 76 Latin America IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 77 Latin America IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 78 Latin America IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 79 Latin America IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 80 Latin America IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 81 Brazil IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 82 Brazil IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 83 Brazil IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 84 Brazil IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 85 Mexico IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 86 Mexico IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 87 Mexico IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 88 Mexico IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 89 Argentina IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 90 Argentina IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 91 Argentina IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 92 Argentina IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 93 MEA IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 94 MEA IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 95 MEA IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 96 MEA IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 97 MEA IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 98 South Africa IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 99 South Africa IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 100 South Africa IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 101 South Africa IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 102 UAE IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 103 UAE IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 104 UAE IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 105 UAE IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)
  • TABLE 106 Saudi Arabia IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Million)
  • TABLE 107 Saudi Arabia IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Million)
  • TABLE 108 Saudi Arabia IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Million)
  • TABLE 109 Saudi Arabia IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 IVD infectious diseases market segmentation
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Primary interviews in North America
  • FIG. 6 Primary interviews in Europe
  • FIG. 7 Primary interviews in Asia Pacific
  • FIG. 8 Primary interviews in Middle East and Africa
  • FIG. 9 Market research approaches
  • FIG. 10 Value-chain-based sizing & forecasting
  • FIG. 11 QFD modeling for market share assessment
  • FIG. 12 Market formulation & validation
  • FIG. 13 IVD infectious disease market snapshot
  • FIG. 14 Segment Insights
  • FIG. 15 Strategy framework
  • FIG. 16 Penetration & growth prospect mapping
  • FIG. 17 Consumer behavior analysis
  • FIG. 18 Factors influencing North America IVD infectious diseases market (%)
  • FIG. 19 Factors influencing Europe IVD infectious diseases market (%)
  • FIG. 20 Factors influencing Asia Pacific IVD infectious diseases market (%)
  • FIG. 21 Factors influencing Latin America IVD infectious diseases market (%)
  • FIG. 22 Factors influencing Middle East and Africa IVD infectious diseases market (%)
  • FIG. 23 Market driver relevance analysis (Current & future impact)
  • FIG. 24 Global population growth, by age group, 2012 - 2021 (Million)
  • FIG. 25 Global percentage of the population, by age group, 2000 and 2050
  • FIG. 26 General trend of CLIA-waived tests
  • FIG. 27 Market restraint relevance analysis (Current & future impact)
  • FIG. 28 Porter's five forces analysis
  • FIG. 29 PESTLE analysis
  • FIG. 30 Strategy mapping
  • FIG. 31 IVD infectious diseases market: Product movement analysis
  • FIG. 32 Product segment dashboard
  • FIG. 33 IVD infectious diseases market product outlook: Key takeaways
  • FIG. 34 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 35 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 36 Software market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 37 IVD infectious diseases market: Technology movement analysis
  • FIG. 38 Technology segment dashboard
  • FIG. 39 IVD infectious diseases market technology outlook: Key takeaways
  • FIG. 40 Immunoassay market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 41 Molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 42 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 43 In Situ Hybridization market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 44 Isothermal Nucleic Acid Amplification Technology (INAAT) market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 45 Chips and microarrays market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 46 Sequencing & NGS market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 47 Transcription Mediated Amplification market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 48 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 49 Microbiology market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 51 IVD infectious diseases market: Technology movement analysis
  • FIG. 52 Application segment dashboard
  • FIG. 53 IVD infectious diseases market technology outlook: Key takeaways
  • FIG. 54 MRSA market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 55 Streptococcus market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 56 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 57 VRE market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 58 CRE market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 59 Respiratory virus market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 60 Candida market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 61 TB & drug-resistant TB market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 62 GI panel testing market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 63 Chlamydia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 64 Gonorrhea market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 65 HPV market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 66 HIV market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 67 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 68 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 69 COVID-19 market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 70 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 71 IVD infectious diseases market: Test location movement analysis
  • FIG. 72 Test location segment dashboard
  • FIG. 73 IVD infectious diseases market test location outlook: Key takeaways
  • FIG. 74 Point of Care market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 75 Central laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 76 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 77 Regional outlook, 2021 & 2030
  • FIG. 78 Regional market dashboard
  • FIG. 79 Regional marketplace: Key takeaways
  • FIG. 80 North America market share and leading players, 2021
  • FIG. 81 Europe market share and leading players, 2021
  • FIG. 82 Asia Pacific market share and leading players, 2021
  • FIG. 83 Latin America market share and leading players, 2021
  • FIG. 84 Middle East and Africa market share and leading players, 2021
  • FIG. 85 North America, SWOT
  • FIG. 86 Europe, SWOT
  • FIG. 87 Asia Pacific, SWOT
  • FIG. 88 Latin America, SWOT
  • FIG. 89 Middle East and Africa, SWOT
  • FIG. 90 North America
  • FIG. 91 North America IVD infectious diseases market, 2018 - 2030 (USD Million)
  • FIG. 92 U.S.
  • FIG. 93 U.S. IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 94 Canada
  • FIG. 95 Canada IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 96 Europe
  • FIG. 97 Europe IVD infectious diseases market, 2018 - 2030 (USD Million)
  • FIG. 98 U.K.
  • FIG. 99 U.K. IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 100 Germany
  • FIG. 101 Germany IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 102 Spain
  • FIG. 103 Spain IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 104 France
  • FIG. 105 France IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 106 Italy
  • FIG. 107 Italy IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 108 Asia Pacific
  • FIG. 109 Asia Pacific IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 110 Japan
  • FIG. 111 Japan IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 112 China
  • FIG. 113 China IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 114 India
  • FIG. 115 India IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 116 South Korea
  • FIG. 117 South Korea IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 118 Australia
  • FIG. 119 Australia IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 120 Latin America
  • FIG. 121 Latin America IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 122 Brazil
  • FIG. 123 Brazil IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 124 Mexico
  • FIG. 125 Mexico IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 126 Argentina
  • FIG. 127 Argentina IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 128 MEA
  • FIG. 129 MEA IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 130 South Africa
  • FIG. 131 South Africa IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 132 Saudi Arabia
  • FIG. 133 Saudi Arabia IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 134 UAE
  • FIG. 135 UAE IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 136 Ansoff Matrix
  • FIG. 137 Heat map analysis
  • FIG. 138 Company market share analysis
  • FIG. 139 Company market position analysis
  • FIG. 140 Company market share, by region, 2021
  • FIG. 141 Market differentiators
目次
Product Code: 978-1-68038-716-2

Infectious Disease In Vitro Diagnostics Market Growth & Trends:

The global infectious disease in vitro diagnostics market size is expected to reach USD 56.60 billion by 2030, registering a CAGR of -7.4% from 2022 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases, such as tuberculosis & COVID-19, and technological advancements are projected to drive the product demand in the coming years. The rising prevalence of multi-drug resistant infections is enhancing the early diagnosis of infectious diseases. For instance, MDR infections are highly common in ICU patients, as per the Microbial Drug Resistance Journal in 2021, the prevalence of MDR infections in critically ill SARS-CoV-2 patients ranged between14% and 50%.

The delay in diagnosis and treatment with antibiotics before infection diagnosis is further escalating the prevalence of drug resistant-bacteria, creating a lucrative opportunity for industry growth. The industry is witnessing a significant number of product launches to meet the demands of consumers. For instance, in May 2022, BD introduced its automated diagnostic platform for infectious diseases in the U.S. The system allows the loading of 1700 specimens and the need for specimen sorting is also eliminated, thereby, reducing errors. Products offered by various competitors have been strategically priced to increase competitive rivalry.

However, complexity in buying behavior increases prominently when consumers have to choose between PoC and lab-based tests owing to differences in sensitivity and beliefs. The industry is oligopolistic with companies, such as Hoffmann-La Roche Ltd., Alere, bioMerieux, and BD, holding the majority of the share collectively. The global industry is price-sensitive, creating rigorous competition among players in terms of manufacturing cost-effective and efficient products. Competitive rivalry is estimated to increase during the forecast period owing to the expected launch of novel biomarker kits. Competitors are adopting key strategies, such as product launches and organizing awareness programs, to gain higher market shares.

Infectious Disease In Vitro Diagnostics Market Report Highlights:

  • The reagents product segment held the largest revenue share in 2021 owing to its high volume usage in testing
  • The molecular diagnostics segment held the largest share in 2021 owing to an increased number of product launches in the segment and increased adoption due to its high accuracy
  • By application, the COVID-19 segment dominated the industry in 2021 due to the high expenditure on testing, to reduce the spread of the virus
  • The central laboratories segment held the highest revenue share in 2021 due to the higher accuracy of laboratory-based tests, which makes them more reliable as compared to PoC and home tests, giving these tests a competitive edge over the other two segments
  • North America dominated the global industry in 2021 due to its favorable regulatory framework, focus on preventive & early testing, and the higher adoption rate of novel diagnostics in this region

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Product
    • 1.1.2 Technology
    • 1.1.3 Application
    • 1.1.4 Test Location
    • 1.1.5 Regional Scope
    • 1.1.6 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
      • 1.3.5.1 Data for primary interviews in North America
      • 1.3.5.2 Data for primary interviews in Europe
      • 1.3.5.3 Data for primary interviews in Asia Pacific
      • 1.3.5.4 Data for primary interviews in Middle East and Africa
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective 1
    • 1.9.2 Objective 2
    • 1.9.3 Objective 3
    • 1.9.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Insights
  • 2.3 Competitive Insights

Chapter 3 IVD Infectious Disease Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 User Perspective Analysis
    • 3.3.1 Consumer behavior analysis
    • 3.3.2 Market influencer analysis
    • 3.3.3 List of key end users
  • 3.4 Regulatory Framework
  • 3.5 Market Dynamics
    • 3.5.1 Market driver analysis
      • 3.5.1.1 Growing geriatric population
      • 3.5.1.2 Technological advancements
      • 3.5.1.3 High demand for PoC facilities
      • 3.5.1.4 Increasing prevalence of infectious diseases
      • 3.5.1.5 External funding for R&D activities
    • 3.5.2 Market restraint analysis
      • 3.5.2.1 High prices of IVD tests
    • 3.5.3 Industry challenges
      • 3.5.3.1 Presence of ambiguous regulatory framework
  • 3.6 IVD Infectious Disease Market Analysis Tools
    • 3.6.1 Industry Analysis - Porter's Five Forces
    • 3.6.2 PESTLE Analysis
    • 3.6.3 Major deals and strategic alliances analysis
      • 3.6.3.1 New product launch
      • 3.6.3.2 Mergers and acquisitions
      • 3.6.3.3 Expansion
      • 3.6.3.4 Partnerships
      • 3.6.3.5 Marketing & promotions
    • 3.6.4 Market entry strategies

Chapter 4 IVD Infectious Diseases Market - Segment Analysis, By Product, 2018 - 2030 (USD Million)

  • 4.1 Definition and Scope
  • 4.2 Product Type Market Share Analysis, 2021 & 2030
  • 4.3 Segment Dashboard
  • 4.4 Global IVD Infectious Diseases Market, by Product, 2018 to 2030
  • 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 4.5.1 Instruments
      • 4.5.1.1 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.2 Reagents
      • 4.5.2.1 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.3 Software
      • 4.5.3.1 Software market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5 IVD Infectious Diseases Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million)

  • 5.1 Definition and Scope
  • 5.2 Technology Type Market Share Analysis, 2021 & 2030
  • 5.3 Segment Dashboard
  • 5.4 Global IVD Infectious Diseases Market, by Technology, 2018 to 2030
  • 5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 5.5.1 Immunoassay
      • 5.5.1.1 Immunoassay market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.2 Molecular Diagnostics
      • 5.5.2.1 Molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.5.2.3 Polymerase Chain Reaction (PCR)
      • 5.5.2.3.1 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.5.2.4 In Situ Hybridization
      • 5.5.2.4.1 In situ hybridization market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.5.2.5 Isothermal Nucleic Acid Amplification Technology (INAAT)
      • 5.5.2.5.1 Isothermal Nucleic Acid Amplification Technology (INAAT) market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.5.2.6 Chips and Microarrays
      • 5.5.2.6.1 Chips and microarrays market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.5.2.7 Sequencing & NGS
      • 5.5.2.7.1 Sequencing & NGS market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.5.2.8 Transcription Mediated Amplification
      • 5.5.2.8.1 Transcription mediated amplification market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.5.2.9 Others
      • 5.5.2.9.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.3 Microbiology
      • 5.5.3.1 Microbiology market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.4 Others
      • 5.5.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 IVD Infectious Diseases Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 6.1 Definition and Scope
  • 6.2 Application Type Market Share Analysis, 2021 & 2030
  • 6.3 Segment Dashboard
  • 6.4 Global IVD Infectious Diseases Market, by Application, 2018 to 2030
  • 6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 6.5.1 MRSA
      • 6.5.1.1 MRSA market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.2 Streptococcus
      • 6.5.2.1 Streptococcus market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.3 Clostridium Difficile
      • 6.5.3.1 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.4 Vancomycin-resistant Enterococci (VRE)
      • 6.5.4.1 VRE market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.5 Carbapenem-resistant Enterobacterial Testing (CRE)
      • 6.5.5.1 CRE market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.6 Respiratory Virus
      • 6.5.6.1 Respiratory virus market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.7 Candida
      • 6.5.7.1 Candida market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.8 Tuberculosis (TB) & Drug-resistant TB
      • 6.5.8.1 TB & drug-resistant TB market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.9 Gastrointestinal (GI) Panel Testing
      • 6.5.9.1 GI panel testing market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.10 Chlamydia
      • 6.5.10.1 Chlamydia market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.11 Gonorrhea
      • 6.5.11.1 Gonorrhea market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.12 Human papillomavirus (HPV)
      • 6.5.12.1 HPV market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.13 Human immunodeficiency virus (HIV)
      • 6.5.13.1 HIV market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.14 Hepatitis C
      • 6.5.14.1 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.15 Hepatitis B
      • 6.5.15.1 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.16 COVID-19
      • 6.5.16.1 COVID-19 market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.17 Others
      • 6.5.17.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 IVD Infectious Diseases Market - Segment Analysis, By Test Location, 2018 - 2030 (USD Million)

  • 7.1 Definition and Scope
  • 7.2 Test Location Type Market Share Analysis, 2021 & 2030
  • 7.3 Segment Dashboard
  • 7.4 Global IVD Infectious Diseases Market, by Test Location, 2018 to 2030
  • 7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 7.5.1 Point of Care
      • 7.5.1.1 Point of Care market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.2 Central Laboratories
      • 7.5.2.1 Central laboratories market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.3 Others
      • 7.5.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 IVD Infectious Diseases Market - Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 8.1 Definition & Scope
  • 8.2 Regional Market Share Analysis, 2021 & 2030
  • 8.3 Regional Market Dashboard
  • 8.4 Regional Market Snapshot
  • 8.5 Regional Market Share and Leading Players, 2021
    • 8.5.1 North America
    • 8.5.2 Europe
    • 8.5.3 Asia Pacific
    • 8.5.4 Latin America
    • 8.5.5 Middle East and Africa
  • 8.6 SWOT Analysis
    • 8.6.1 North America
    • 8.6.2 Europe
    • 8.6.3 Asia Pacific
    • 8.6.4 Latin America
    • 8.6.5 Middle East and Africa
  • 8.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
    • 8.7.1 North America
      • 8.7.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.1.2 U.S.
      • 8.7.1.2.1 U.S. IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.1.3 Canada
      • 8.7.1.3.1 Canada IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.2 Europe
      • 8.7.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.2.2 U.K.
      • 8.7.2.2.1 U.K. IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.2.3 Germany
      • 8.7.2.3.1 Germany IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.2.4 Spain
      • 8.7.2.4.1 Spain IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.2.5 France
      • 8.7.2.5.1 France IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.2.6 Italy
      • 8.7.2.6.1 Italy IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.3 Asia Pacific
      • 8.7.3.1 Asia Pacific market estimates and forecast estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.3.2 Japan
      • 8.7.3.2.1 Japan IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.3.3 China
      • 8.7.3.3.1 China IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.3.4 India
      • 8.7.3.4.1 India IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.3.5 South Korea
      • 8.7.3.5.1 South Korea IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.3.6 Australia
      • 8.7.3.6.1 Australia IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.4 Latin America
      • 8.7.4.1 Latin America market estimates and forecast estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.4.2 Brazil
      • 8.7.4.2.1 Brazil IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.4.3 Mexico
      • 8.7.4.3.1 Mexico IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.4.4 Argentina
      • 8.7.4.4.1 Argentina IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.5 MEA
      • 8.7.5.1 MEA market estimates and forecast estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.5.2 South Africa
      • 8.7.5.2.1 South Africa IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.5.3 Saudi Arabia
      • 8.7.5.3.1 Saudi Arabia IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.7.5.4 UAE
      • 8.7.5.4.1 UAE IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 9.1.1 Ansoff matrix
    • 9.1.2 Heat map analysis
  • 9.2 Company Categorization
    • 9.2.1 Innovators
    • 9.2.2 Market Leaders
  • 9.3 Vendor Landscape
    • 9.3.1 List of key distributors and channel partners
    • 9.3.2 Key customers
    • 9.3.3 Key company market share analysis, 2021
  • 9.4 Public Companies
    • 9.4.1 Company market position analysis
    • 9.4.2 Company market share, by region, 2021
    • 9.4.3 Competitive dashboard analysis
      • 9.4.3.1 Market Differentiators
  • 9.5 Private Companies
    • 9.5.1 List of key emerging companies
  • 9.6 Company Profiles
    • 9.6.1 BD
      • 9.6.1.1 Company overview
      • 9.6.1.2 Financial performance
      • 9.6.1.3 Product benchmarking
      • 9.6.1.4 Strategic initiatives
    • 9.6.2 bioMerieux SA
      • 9.6.2.1 Company overview
      • 9.6.2.2 Financial performance
      • 9.6.2.3 Product benchmarking
      • 9.6.2.4 Strategic initiatives
    • 9.6.3 Abbott
      • 9.6.3.1 Company overview
      • 9.6.3.2 Financial performance
      • 9.6.3.3 Product benchmarking
      • 9.6.3.4 Strategic initiatives
    • 9.6.4 Quidel Corporation
      • 9.6.4.1 Company overview
      • 9.6.4.2 Financial performance
      • 9.6.4.3 Product benchmarking
      • 9.6.4.4 Strategic initiatives
    • 9.6.5 OraSure Technologies, Inc
      • 9.6.5.1 Company overview
      • 9.6.5.2 Financial performance
      • 9.6.5.3 Product benchmarking
      • 9.6.5.4 Strategic initiatives
    • 9.6.6 Hologic Inc. (Gen-Probe)
      • 9.6.6.1 Company overview
      • 9.6.6.2 Financial performance
      • 9.6.6.3 Product benchmarking
      • 9.6.6.4 Strategic initiatives
    • 9.6.7 Cepheid (Danaher)
      • 9.6.7.1 Company overview
      • 9.6.7.2 Financial performance
      • 9.6.7.3 Product benchmarking
      • 9.6.7.4 Strategic initiatives
    • 9.6.8 QIAGEN
      • 9.6.8.1 Company overview
      • 9.6.8.2 Financial performance
      • 9.6.8.3 Product benchmarking
      • 9.6.8.4 Strategic initiatives
    • 9.6.9 F. Hoffmann-La Roche Ltd.
      • 9.6.9.1 Company overview
      • 9.6.9.2 Financial performance
      • 9.6.9.3 Product benchmarking
      • 9.6.9.4 Strategic initiatives
    • 9.6.10 Siemens Healthcare GmbH
      • 9.6.10.1 Company overview
      • 9.6.10.2 Financial performance
      • 9.6.10.3 Product benchmarking
      • 9.6.10.4 Strategic initiatives
    • 9.6.11 Bio-Rad Laboratories, Inc.
      • 9.6.11.1 Company overview
      • 9.6.11.2 Financial performance
      • 9.6.11.3 Product benchmarking
      • 9.6.11.4 Strategic initiatives